TAG:
genetic testing
Steep Sentence Underscores Scrutiny of Genetic Testing
By Janette Wider | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
The sentencing tied to a $522 million genetic testing fraud scheme is more than just the latest fraud headline for clinical laboratory professionals. Instead, it serves as another warning that federal scrutiny surrounding genetic testing is continuing and unlikel…
Risk of Complacency May Be the Biggest Threat
By R. Lewis Dark | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
Prevailing sentiment at the recent Executiv…
Expect RESULTS Act Vote by End of the Year
By Scott Wallask | From the Volume XXXIII, No. 7 – May 26, 2026 Issue
CEO SUMMARY: Evidence at the 2026 Executive War College suggests a coming push in clinical lab advocacy, focusing on the RESULTS Act to establish a permanent, database-driven reimbursement model. Simultaneously, federal regulators have floated the idea of heightened scruti…
Payers Unleash AI to Dissect Outlier Billing Patterns
By Janette Wider | From the Volume XXXIII, No. 6 – May 04, 2026 Issue
Diagnostic laboratories can follow every clinical guideline, employ the most talented clinical lab professionals, and provide life-saving data to patients, yet still find themselves in the crosshairs of a federal or payer audit. The culprit is …
Clinical Labs Must Prep for Heightened Audits
By Janette Wider | From the Volume XXXIII, No. 3 – March 2, 2026 Issue
CEO SUMMARY: A new report from the Office of Inspector General sheds interesting light on just how much genetic testing has increased among Medicare Part B beneficiaries. With billions of dollars in reimbursement at stake for clinical laboratories, expect federal officials…
Don’t Let the Payers Enjoy All the Benefits of Data
By R. Lewis Dark | From the Volume XXXII, No. 11 – August 4, 2025 Issue
PROBABLY SINCE THE ADVENT OF M…
Regeneron Loses 23andMe Bid to TTAM Research Institute
By Jillia Schlingman | From the Volume XXXII, No. 9 – June 23, 2025 Issue
23andMe FOUNDER AND FORMER CEO ANNE WOJCICKI has successfully retained control over her company by selling it to her nonprofit medical research firm TTAM Research Institute for $305 million. This followed bidding between TTAM Research Institute and Regeneron Pharmac…
As 23andMe Faces Bankruptcy, Home Testing Shows Warts
By Robert Michel | From the Volume XXXII, No. 7 – May 12, 2025 Issue
HIGH-STAKES DRAMA SURROUNDING 23ANDME’S BANKRUPTCY—including CEO Anne Wojcicki resigning to try to bid for the company she cofounded and state prosecutors urging caution about the data privacy of the company’s customers—brings up a fundamental question regarding d…
Review of Genetic Testing Companies During 2024
By Robert Michel | From the Volume XXXII, No. 1 – January 6, 2025 Issue
CEO SUMMARY: Investors in genetic testing companies are taking it on the chin these days. During 2024, a number of the nation’s largest firms providing genetic test services reported significant losses. Other genetic testing companies are dealing with class action lawsuits claiming that…
November 25, 2024, Intelligence: Late-Breaking Lab News
By Robert Michel | From the Volume XXXI, No. 16 – November 25, 2024 Issue
Disruption is happening in the consumer genetic testing marketplace. In recent weeks, news outlets in the United Kingdom reported that Atlas Biomed, a consumer genetic testing company founded in 2016, had simply “disappeared.” Malwarebytes said Atlas Biomed’s “London offices …
CURRENT ISSUE
Volume XXXIII, No. 9 – July, 2026
Newsmaker Interview with Revvity’s Yves Dubaquie > How Specialty Diagnostic Tests Connect with Lab Customers: In this exclusive Q&A, Revvity’s Yves Dubaquie provides details about the in vitro diagnostics company’s priorities, including developing specialty tests and reviewing its business in China. Dubaquie also explains why clinical laboratories may need to consider hiring more technology-savvy workers in the future as the complexity of instruments grows.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized